COVID-19 PANDEMIC UPDATES
|
Learn more

Customer Letters

Please note: The following Customer Letters, do not replace the version that you receive from your local Canadian Blood Services site.

* The contents of the customer letters available on this site are current as of their dates of publication. If required, contact your local Hospital Liaison Specialist to determine if the letter is still current. 

Category
done
done
done
Displaying 1 - 30 of 30
Date Sort ascending
CL_2020-30.pdf

INFORMATION ONLY
GamaSTAN® Product Update

Customer Letter 2020-30 (PDF) | Gamastan (IG-C) Update LetterProduct Profile GamaSTAN 

CL_2020-29_0.pdf

INFORMATION ONLY
Bi-Weekly Inventory Update: Plasma Protein and Related Products

Customer Letter 2020-29 (PDF)

CL_2020-28.pdf

ACTION REQUIRED
Provision of K Negative Red Blood Cells for Females 45 Years and Under

Customer Letter 2020-28 (PDF)

CL_2020-27.pdf

ACTION REQUIRED
New Unique Pool Number for Exchange Transfusion

Components For Hospital Customers in Manitoba Only

Customer Letter 2020-27 (PDF)

CL_2020-26.pdf

INFORMATION ONLY
Move of Canadian Blood Services Operations, Calgary

Customer Letter 2020-26 (PDF)

CL_2020-25.pdf

INFORMATION ONLY
Gammagard Liquid 30g Inventory Alert

Customer Letter 2020-25 (PDF)

CL_2020-24.pdf

ACTION REQUIRED
Convalescent Plasma Component Codes and Information

Customer Letter 2020-24 (PDF)

CL_2020-23.pdf

INFORMATION ONLY
CSL Behring - Safety Seal Information

Customer Letter 2020-23 (PDF) | CSL Behring - Safety Seal Information

CL_2020-22.pdf

INFORMATION ONLY
Updates to Héma-Québec Component Codes for Deglycerolized Components

Customer Letter 2020-22 (PDF)

CL_2020-21.pdf

INFORMATION ONLY
Electronic Fillable Patient Requisition Forms

Customer Letter 2020-21 (PDF)

CL_2020-20.pdf

INFORMATION ONLY
Known Interference Between Rebinyn® and Laboratory Assays used to Diagnose Coagulopathy Caused by COVID-19 Infection

Customer Letter 2020-20 (PDF) | REBINYN assay statement in COVID-19 patients

CL_2020-19.pdf

INFORMATION ONLY
Changes to Request Patient Designated Plasma Protein Products for Panhematin®

Customer Letter 2020-19 (PDF) | Sample Request for Patient Designated Plasma Protein Products

CL_2020-18.pdf

INFORMATION ONLY
COVID-19 Convalescent Plasma Production

Customer Letter 2020-18 (PDF)

CL_2020_17.pdf

INFORMATION ONLY
Exterior Cleansing of Shipping Containers and Blood Bags

Customer Letter 2020-17 (PDF) | NAC IP+C Appendix A COVIDNAC IP+C for Blood Return to Inventory

CL_2020-16.pdf

INFORMATION ONLY
Additional Infection Control Measures

Customer Letter 2020-16 (PDF)

CL_2020-15.pdf

INFORMATION ONLY
Known Interference Between Hemlibra® and Laboratory Assays used to Diagnose Coagulopathy Caused by COVID-19 Infection

Customer Letter 2020-15 (PDF) | COVID 19 and Hemlibra interactions with labs to diagnose DIC

CL_2020-14_0.pdf

ACTION REQUIRED
Fibrinogen Concentrate – Educational Resources and Supply

Customer Letter 2020-14 (PDF) | CSL RiaSTAP Customer letterCSL Medical Information Request Form | Fibryga Customer Letter

CL_2020-13.pdf

INFORMATION ONLY
Shipment of Patient Samples to Diagnostic Services Ontario and Nunavut (ONN) Laboratory
Southern and Central Ontario Hospitals Only

Customer Letter 2020-13 (PDF)

CL_2020-12.pdf

INFORMATION ONLY
Takeda’s Patient Support Program (OnePath)

Customer Letter 2020-12 (PDF) | Takeda Patient Letter

CL_2020-11_0.pdf

INFORMATION ONLY
COVID-19

Customer Letter 2020-11 (PDF)

CL_2020-10.pdf

INFORMATION ONLY
Update for HLA/HPA Results Printed on Apheresis Platelet End Label

Customer Letter 2020-10 (PDF)

CL_2020-09.pdf

INFORMATION ONLY
Eloctate® Supply Constraint

Customer Letter 2020-09 (PDF)

CL_2020-08.pdf

INFORMATION ONLY
Introduction of Jivi®

Customer Letter 2020-08 (PDF) | Jivi Product Profile | Introducing Jivi HCP Letter | Sample Request Patient Designated Plasma Protein Products

CL_2020-07.pdf

INFORMATION ONLY
WinRho® SDF Canadian Labelled Product - Labelling Error

Customer Letter 2020-07 (PDF) | Saol CBS WinRho SDF Customer Letter

CL_2020-06.pdf

INFORMATION ONLY
Immune Globulin Plan – Additional Information

Customer Letter 2020-06 (PDF) | Cutaquig product info ProCare (PDF)DCL for CSL IG Availability (PDF)Panzyga Customer Letter (PDF)

CL_2020-05.pdf

INFORMATION ONLY
Kovaltry® Infusion Set Change

Customer Letter 2020-05 (PDF) | Kovaltry Infusion Set Change

CL_2020-04.pdf

INFORMATION ONLY
Transfer of Routine Saskatchewan Prenatal ABO-Rh and Antibody Testing from Canadian Blood Services Vancouver to Saskatchewan Hospitals

Customer Letter 2020-04 (PDF)

CL_2020-03.pdf

INFORMATION ONLY
Cinryze® Supply – Additional Information

Customer Letter 2020-03 (PDF) | CINRYZE Blood Bank Director Letter - January 2020

CL_2020-02.pdf

INFORMATION ONLY
Ottawa National Immunohematology Reference Laboratory (NIRL) Relocation to the Brampton Operations Site

Customer Letter 2020-02 (PDF)

CL_2020-01.pdf

INFORMATION ONLY
HLA/HPA Results Printed on Apheresis Platelet End Label

Customer Letter 2020-01 (PDF)